NCT03829410 - Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

January 29, 2024

Study Completion Date

January 29, 2024

Conditions

Metastatic Colorectal CancerKRAS Gene Mutation

Interventions

DRUG

Onvansertib

Onvansertib orally.

BIOLOGICAL

Bevacizumab

Bevacizumab intravenously.

DRUG

FOLFIRI

FOLFIRI intravenously.

Trial Locations (7)

Inova Schar Cancer Institute, Fairfax

Mayo Clinic Florida, Jacksonville

Mayo Clinic Rochester, Rochester

University of Kansas Medical Center Research Institute, Kansas City

CARTI Cancer Center, Little Rock

Mayo Clinic Cancer Center, Phoenix

USC Norris Comprehensive Cancer Center, Los Angeles